RE:RE:ADK ... Google ... Perception and Trust !And just so the everyone understands, this is actually a good thing for Diagnos shareholders, because it means the market is growing. It is one thing to have working technology, but another for the market to be ready to buy it (which hasn't happened yet). There is a book called "The Gorilla Game" that describes the strategy for investing in tech stocks. Having lots of new companies commercializing a technology actually helps grow sales for all of them, which might sound counter intuitive, until you realize that every hospital in the US would want to compare suppliers for different DR screening systems. The more hospitals adopt it, the more it puts pressure on other hospitals to do the same. Some will choose IBM but others will chose ADK. And as the market grows, there will be more big players looking to jump in. They could make a splash by buying ADK (some people have already said they are willing to sell for $1/share, or $150m, which is easier than a company spending 10 years on R&D).
jammer4444 wrote: Google violating privacy rules is nothing new.. But something investors might be curious to learn is that another competitor, IDx has partnered with IBM Watson, and is filing for FDA approval:
IDx, an early-stage medical device company focused on developing software-based algorithms that can identify disease in medical images is currently conducting an FDA clinical trial to obtain clearance for its first product, IDx-DR by the end of summer 2017. IDx-DR is a screening solution for diabetic retinopathy. IDx also has algorithms in development for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk. https://hitconsultant.net/2017/07/06/new-ai-device-diabetes-eye-screening/
Today IBM (NYSE: IBM) Watson Health and IDx announced a five-year strategic alliance to advance global eye health through cognitive computing applications. This announcement comes shortly after IBM announced that IDx joined the IBM Watson Medical Imaging Collaborative, which includes 24 healthcare leaders worldwide.
The partnership leverages more than a decade of IDx's medical image analysis work and IBM's global reach, and aims to help patients with serious eye conditions. As part of the alliance, IBM Watson Health intends to distribute IDx's automated diabetic retinopathy (DR) screening solution, IDx-DR, in the 31 countries that comprise the European Economic Area. This distribution may be expanded to Australia, Canada, and the United States pending regulatory approval.
https://www.eyediagnosis.net/single-post/2017/03/08/IBM-WH-OEM